Michael Ronthal, MD
Nothing to disclose
Jeremy M Shefner, MD, PhD
Grant/Research/Clinical Trial Support: BiogenIdec; Neuraltus; Cytokinetics; Neuraltus; Sanofi-Aventis (ALS). Consultant/Advisory Boards: BiogenIdec; Cytokinetics; ISIS; Trophos; Asubio; Glaxo SmithKline (ALS).
John F Dashe, MD, PhD
Employee of UpToDate, Inc. Equity Ownership/Stock Options: Pfizer, Inc.
Conflict of interest policy
The material and recommendations in UpToDate represent the best judgment of the authors based on their evaluation of the literature. What studies they select to discuss and their analysis of them are necessarily subjective. Bias may be extremely difficult to detect because these articles may contain no primary data to speak for themselves. For this reason, we make full disclosure to our readers of potential conflicts of interests and may elect, at the discretion of the Editor-in-Chief, not to publish material written by an author with a conflict in a controversial therapeutic area. This policy is not intended to suggest or condone bias in any presentation but is used to provide our subscribers with information that might be of potential importance to their evaluation of the material. Deputy Editors may not accept funds from "educational" arms of health industry organizations (such as speaker's bureaus).
Under the accreditation guidelines by which UpToDate is approved to award continuing medical education (CME) credits, we are required to collect information on relevant financial relationships with commercial interests from individuals including those of their spouses and partners who are in a position to control the content of continuing medical education. These individuals include authors, in-house editorial staff, editors-in-chief, and peer reviewers. In the case that this information is not provided, we are obligated to prohibit those individuals from participating in the editorial process. Their involvement will cease and a new individual will be selected.
Disclosures are available by clicking on the link at the top of each topic.
This policy last reviewed on June 11, 2012.